COLLEGIUM PHARMACEUTICAL, INC (COLL) Stock
COLL has an Alpha Score of 39 out of 100 (weak), computed on Oct 30, 2026 from 3 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported COLL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $49.47M. Its trailing P/E ratio is 15.5 and its net margin 5.9% (key statistics as of Oct 24, 2026).
What is COLL's Alpha Score?
How it works →Alpha Score of 39 reflects weak overall profile with poor momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own COLL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.37M | $49.47M | -7% |
| Millennium Management Israel Englander | 737K | $26.68M | +104% |
| D.E. Shaw David Shaw | 338K | $12.25M | -36% |
| Marshall Wace | 253K | $9.17M | -66% |
| Point72 Steve Cohen | 114K | $4.13M | NEW |
| Citadel Ken Griffin | 69K | $2.48M | -43% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are COLL's key statistics?
Key statistics as of Oct 24, 2026
How does COLL's valuation compare with the Healthcare sector?
| Metric | COLL | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 15.5 | 27.1 | 97 |
| Net margin | 5.93% | 5.48% | 139 |
| Return on equity | 15.96% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
COLL price chart
Powered by TradingViewWhat does COLLEGIUM PHARMACEUTICAL, INC do?
Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in extended-release and immediate-release formulations, along with Symproic for opioid-induced constipation. The company employs proprietary DETERx platform technology designed to maintain safety profiles while deterring abuse through various manipulation methods. Headquartered in Stoughton, Massachusetts, and founded in 2002, Collegium serves healthcare providers and patients across the United States, positioning itself as a leader in responsible pain management and ADHD treatment.